Eidos Therapeutics, Inc. (EIDX)

128.44 +5.91 (+4.82%) At close: 4:00PM EST

Eidos Therapeutics, Inc.

101 Montgomery Street
Suite 2000
San Francisco, CA 94104
United States
415 887 1471
http://www.eidostx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 70

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Neil Kumar	CEO & Director	247.68k	N/A	1979
Dr. Uma Sinha	Chief Scientific Officer & Director	533.4k	N/A	1957
Dr. Cameron Turtle DPHIL, Ph.D.	Chief Bus. Officer	578.4k	N/A	1990
Dr. Jonathan C. Fox FACC, M.D., Ph.D.	Pres & Chief Medical Officer	N/A	N/A	1957
Dr. Isabella Graef M.D.	Co-Founder & Board Advisor	N/A	N/A	1965
Dr. Mamoun Alhamadsheh Ph.D., Pharm.D.	Co-Founder	N/A	N/A	N/A
Mr. Franco Valle	Sr. VP of Fin., Principal Accounting Officer & Sec.	N/A	N/A	1981
Mr. Matt Outten	Chief Commercial Officer	N/A	N/A	N/A
Dr. Hoyoung Huh	Consultant	N/A	N/A	1969

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Corporate Governance

Eidos Therapeutics, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.